Britain and America have concluded a key bilateral deal that will maintain no import taxes on British drug exports being sold in the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to raise spending on drugs through the National Health Service (NHS). This move guarantees that tariffs on these crucial products will remain at zero for a timeframe of the next three years.
This deal follows previous threats to dramatically increase duties on patented pharmaceutical products, with potential rates floated as high as one hundred percent.
"This deal between the United Kingdom bolsters the global environment for new treatments and brings long-overdue equity to American-British drug exports," an announcement said.
Commercial Importance
Pharmaceuticals constitute one of the Britain's largest exports to the US, which is easily the largest buyer for major companies like GSK and AstraZeneca.
Export figures show that in the year prior to the third quarter, the UK sold drugs totaling billions to the US. This amount accounted for nearly one-fifth of total UK exports in that period.
"This agreement safeguards jobs, boosts capital expenditure and facilitates the UK to become a worldwide center for biotech and pharma," a government official remarked.
Specific NHS Changes
The agreement includes several notable changes from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a aim to double total NHS spending on medicines from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must return to the NHS to prevent overspending will be capped at 15%. In the past, rebates exceeded 20%.
Recent Tensions
The pact comes amid a long-running tension between the pharmaceutical industry and the British authorities over spending levels and approval rates.
These tensions were intensified by claims that US consumers were paying several times more for the equivalent treatments than patients in the UK and Europe.
Recently, several significant drug company projects in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been announced toward US facilities.
A senior figure stated that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had decreased as a share of its resources over the previous ten-year period.
